Molecular Biometrics LLC
This article was originally published in Start Up
Executive Summary
The success rates for in vitro fertilization are rather low--about 34%--and although this isn't much worse than the odds that nature offers for getting pregnant, for the couple that has elected to undergo IVF this risk-benefit proposition is difficult to bear. Molecular Biometrics helps to improve the outcomes of IVF with a diagnostic that determines embryo health.
You may also be interested in...
Start-Up Previews (07/2007)
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Start-Ups in Obesity," "New Technologies for Infertility," and "New Zealand Biotech." Plus these Start-Ups Across Health Care: Intelect Medical, N Spine, and Solace Pharmaceuticals.
New Technologies for Infertility
The infertility market has historically been dominated by drugs. There have been few product opportunities on the medtech side, which has consisted of commodity products like syringes, petri dishes and microscopes. But that is changing; recently several new companies have been founded with technologies to improve the success rates of in vitro fertilization. VCs have also come to realize that infertility represents a premium, self-pay market for elective procedures.
Start-Up Previews (07/2007)
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Start-Ups in Obesity," "New Technologies for Infertility," and "New Zealand Biotech." Plus these Start-Ups Across Health Care: Intelect Medical, N Spine, and Solace Pharmaceuticals.